The European Commission has approved Bexsero Meningococcal Group B Vaccine for use in individuals 2 months of age and older.
MenB disease is a bacterial infection and is the leading cause of meningitis across Europe, particularly in infants. The disease is rare but can strike rapidly and prove fatal, so prevention through vaccination is important.
The Meningitis Trust welcomed the licensing of Bexsero and is urging governments to include the vaccine in national immunization programmes.